AU595091B2 - Thiopyranodipyrazoles - Google Patents
Thiopyranodipyrazoles Download PDFInfo
- Publication number
- AU595091B2 AU595091B2 AU10726/88A AU1072688A AU595091B2 AU 595091 B2 AU595091 B2 AU 595091B2 AU 10726/88 A AU10726/88 A AU 10726/88A AU 1072688 A AU1072688 A AU 1072688A AU 595091 B2 AU595091 B2 AU 595091B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- compounds
- compound
- thiopyrano
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000003182 bronchodilatating effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- -1 5-substituted thiopyrano[3,4-c]pyrazol-4(1H)-one Chemical class 0.000 abstract description 5
- 229940124630 bronchodilator Drugs 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 239000000168 bronchodilator agent Substances 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SEMXWBFSIDIGPO-UHFFFAOYSA-N 1,5-dihydropyrazol-4-one Chemical compound O=C1CNN=C1 SEMXWBFSIDIGPO-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PQUGCKBLVKJMNT-UHFFFAOYSA-N SC560 Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000005092 tracheal tissue Anatomy 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention is directed to a group of compounds which are variously methylated thiopyranodipyrazoles and to the S-oxides and S-dioxides of such compounds. The compounds are useful as bronchodilators and are prepared by the reaction of appropriately 5-substituted thiopyrano[3,4-c]pyrazol-4(1H)-one with a hydrazine.
Description
AUSTRALIA
Patents Act COMLEE95091~hIC
(ORIGINAL)
Class Int. Class Application Number: Lodged: Complete Specificaticn Lodged: Accepted: Pubished: Priority *,Related Art: APLCN' Naes fAplcn*) Amde(es) of Applicant(s): 2110 East Galbraith Road, Cincinnati, Ohio, UNITED STATES OF AMERICA.
SAddress for Service is: !2HILLIPS OWI*NDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Complete Specification gor the invention entitled: 1HIOMI*AM~ tIPYRAZOLES Our Ref 80403 POP Code: 1432/1432 The following statement is a full description of this invention including the best method of performing it known to applicant(s): 60000q/ 1 1 P11ILLIPS ORMONDE i'ITZPATRICK Patent and Trademark Attorneys 367 Collins Street Melbourne, Australia lX59 R 7
THIOPYRANODIPYRAZOLES
0 4^ 490 01 00f 4 c e f lt S c 4 lG C r C C C 4 1( 1 00 9 0S 00 0 00 0@ The present pounds which are oxides thereof.
is directed to a invention is directed to a group of commethylated thiopyranodipyrazoles and S- More particularly, the present invention group of compounds having the formula:
R
1
N
-IR4
R
2 (O)nS wherein R
I
R
2 R3 and R4 are each independently hydrogen or methyl with R 1 and R3 being positioned on one of the nitrogens in their respective rings with the other nitrogen then being doubly bonded to the adjacent carbon; the dotted 30 lines indicate the presence of two conjugated double bonds with the specific position of the double bonds being determined by the position of the R 1 or R3 sibstituents; and n is 0, 1 or 2. The present invention further encompasses the pharmaceutically acceptable acid addition salts of the aforesaid compounds.
M01259 Acid addition salts of the aforesaid compounds with pharmaceutically acceptable acids are equivalent to the above amines for the purposes of this invention. Illustrative of such salts are the salts with inorganic acids such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric and like acids; with organic carboxylic acids such as, for example, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, malic, tartaric, citric, asco bic, maleic, hydroxymaleic and dihydroxymaleic, benzoic, phenylacetic, 4-aminobenzoic, 4-hydroxybenzoic, anthranilic, cinnamic, salicyclic, 4-aminosalicyclic, 2-phenoxybenzoio, 2-acetoxybenzoic, mandelic and like acids; and with organic sulfonic acids such as methanesulfonic acid and p-toluenesulfonic acid.
o 15 Preferred embodiments of the present invention are those compounds wherein n is 0.
c The compounds of the present invention are prepared by the reaction of a hydrazine of the formula
SR
1
-NHNH
2 20 wherein R 1 is hydrogen or methyl, with a 1,3-diketone of the formula o. O 0 0 0 SII I /R4 oo
C
a AR2 M01259 -2r i wherein R2, R 3 and R4 are each independently hydrogen or methyl. The reaction is carried out with heating in an inert solvent such as an alcohol, with methanol being preferred. The product obtained, in which n is 0, is optionally oxidized with a peroxybenzoic acid to give those compounds in which n is 1 or 2. When R1 or R3 is hydrogen, the product is further optionally treated with sodium hydride and methyl iodide in an inert solvent such as dimethylformnide to give the corresponding compounds wherein R 1 or R3 is methyl. When the process gives a mixture of products with substitution on either nitrogen in the rings in question, the resultant mixture is separated Sby chromatography.
00 0 po The 1,3-diketone used as the starting material above 15 can be prepared from a thiopyranopyrazolone of the formula 0000 0 0 0 0000 0 0 0 000 0 O This ketone is reacted with a strong base and an appropriate carbonyl compound to give the diketone. More .o a specifically, sodium hydride and ethyl formate or a com- 20 bination of diisopropylamine, n-butyllithium and acetyl 0 S0O chloride are used.
The substituted dipyrazole compounds as described herein are bronchodilators and are thus useful in the treatment of bronchial disolders such as bronchial asthma.
The present invention is further directed to a method of effecting bronchodilation.
M01259 -3- In practicing the method of this invention, an effective bronchodilating amount of 1 or more substituted dipyrazoles of this invention is administered internally to a mammal in need thereof by a route effective to bring the compound into contact with the bronchial and tracheal tissues of the mammal. Administration can be carried out either by a parenteral route, such as by intravenous, intraperitoneal or intramuscular injection, or by introduction into the gastrointestinal tract via oral or rectal administration, for example, in order to bring about such contact via the blood stream, or by intratracheal administration, by inhalation of a solution in the form of a So0o spray, for example.
0 0 0 09 0 0 o. The effective bronchodilating amount of the compound, "o 15 that is, the amount sufficient to inhibit or alleviate 9bronchial spasm, depends on various factors such as the *roo0c size, type and age of the animal to be treated, the particular compound or pharmacologically-acceptable salt employed, the route and frequency of administration, the 20 severity of any spasm and the causative agent involved, and 4o the time of administration. In particular cases, the dosage to be administered can be ascertained by conven- °00 tional range finding techniques, for example, by observing the bronchodilator activity produced at different dosage 25 rates. More specifically, the compounds can be adminis- 0 o 00 tered at dosage rates ranging from about 0.2 to about 100 "a milligrams of substituted dipyrazole compound per kilogram of animal body weight with other ranges being from about to about 20 or from 1 to about 5 milligrams per kilogram. It is generally desirable to administer individual dosages at the lowest amount which provides the desired protection from bronchial spasm consonant with a convenient dosing schedule. Dosage units adaptable to oral administration such as tablets, capsules, lozenges, elixirs, M01259 _C1~ syrups and the like are generally preferred and the active compound can be formulated in conventional time release capsule or tablet formulations although injectable compositions or sprays and aerosols for inhalation are preferred when rapid action is desired. In an example of an individual dosage unit, a tablet would contain 200 mg of active ingredient and would be administered 1 to 6 times daily or, preferably, 2 to 4 times daily.
In practicing the method of the invention, the active ingredient is preferably incorporated in a composition comprising a pharmaceutical carrier and from about 5 to about 90 percent by weight of the substituted dipyrazole compound C or a pharmaceutically-acceptable salt thereof. The term a' "pharmaceutical carrier" refers to known pharmaceutical s 15 excipients useful in formulating pharmaceutically active compounds for internal administration to animals, and which are substantially non-toxic and non-sensitizing under conditions of use. The compositions can be prepared by known techniques for the preparation of tablets, capsules, lozent t 20 ges, troches, suppositories, elixirs, syrups, emulsions, dispersions, wettable and effervescent powders, sterile injectable compositions and solutions for sprays, and can .o 0 contain suitable excipients known to be useful in the preparation of the particular type of compositions desired.
Suitable pharmaceutical carriers and formulation techniques O" o are found in standard texts, such as Remington's ao Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.
In evaluating bronchodilator activity, test compounds were administered to guinea pigs by intraperitoneal injection or orally and the guinea pigs were challenged by exposure to a histamine aerosol at periods ranging from minutes to 4 hours later. Untreated animals collapsed when M01259 ~II~ L~ I_ ii_ exposed to the histamine aerosol. In the operations, the animals were observed and collapse times were recorded.
The collapse times observed were then compared statistically with control animals treated with water alone with the control group usually being a long-term cumulative control. The actual dose of test compound administered was generally 30% of the LD50 administered intraperitoneally.
Some specific doses of compounds used in the testing are as follows: 5,6-Dihydro-6-methyl-lH-thiopyrano[3,2-c:5,4-c']dipyrazole; 110 mg/kg.
5,6-Dihydro-6-methyl-lH-thiopyrano[3,2-c:5,4-c' dipyrazole 4-oxide; 163 mg/kg.
5,6-Dihydro-6-methyl-iH-thiopyrano[3,2-c:5,4-c' dipyrazole 4,4-dioxide; 163 mg/kg.
When tested by the above procedure, the compounds of the present invention were found to produce a bronchodilating 4.°4 effect.
The following examples are presented to illustrate the present invention but they should not be construed as limiting it in any way.
o 4.
*EXAMPLE 1 A mixture of sodium hydride (8.8 g of a 60% suspension in mineral oil), 8.9 ml of ethyl formate, 3 drops cf ethanol and 400 ml of tetrahydrofuran was prepared and stirred as a solution of 18.5 g of l-methyl-5,7-dihydrothiopyrano[3,4-c]pyrazol-4(1H)-one in 100 ml of tetrahydrofuran was added dropwise. The mixture was heated at reflux for 4 hours and cooled. It was diluted with 200 ml of M01259 -6water and 100 ml of ethyl ether and stirred briefly. Th e aqueous layer was separated and washed with dichloromethane and then acidified with aqueous hydrochloric acid. The solid which formed was separated by filtration and dried to give an off-white solid which was l,4,5,7-tetrahydro-lmethyl-4-oxothiopyrano [3,4-c melting at about 158-160 0 C. An analytical sample, melting at about 158-159 0 C, was obtained by recrystallization from ether and dichioromethane.
If the above procedure is repeated using 1,3-dimethyl- 5,7-dihydrothiopyrano[3,4-cpyrazol-4(l)-c~re, the product obtained is l,4,S,7-.tetrahydro-l,3-dimethyl-4-oxothiopyrano[3,4-clpyrazole-5-carboxaldehyde. [The necessary starting material is obtained by following the procedures described by G. Menozzi et al., J. Het. Chem., 21 1437 (1984) and H. Smith, J.Chm Soc., 803 (1953).] ,Tf the procedure of the first paragraph is repeated using dilisopzcopylamine, n-butyllithium in hexane, and acetyl chlorid~e t~n place of the sodium hydride and ethyl formate, the product obtained is 5-acetyl-5,7-dihydro-lmethyithiopyrano [3,4-clpyrazol-4 (lH)-one.
EXAMPLE 2 Hydrazine (3.5 ml) wais added dropwise to a sclution of 41, l45 7-tetrahydro-l-wthy-4-oxothi.opyrano[3,4-clpyrazole- 5-carboxaldehyde in 250 ml of methanol. The r*8ulting solution was heated at reflux for 45 minutes and then stirred at room temperature for 16 hours. The solvent was removed under reduced pressure and the residue was triturated with ether to g,1re an orange solid (93% yield) melting at about 196-200 0 C. Recr rstallization of this molid from a mixture of ethanol oind water gave 5r6-clihydro- M01259 7 -7- 6-methyl-"lH-thiopyranof3,2-c:5,4k-c']dipyrazole melting at about 224-226 0
C.
If the above procedure is repeated using hydrazine and the appropriate diketones, there is obtained 5,6-dihydro- 6,8-dimethyl-lH-thiopyrano[3,2-c:5,4-c'ldipyrazole and 5,6dihydro-3,6-dimethyl-lH-thiopyrano[3,2-c:5,4-c'Jdipyrazole.
If the procedure of th. 4 irst paragraph is repeated using the same carboxaldehyde but using methyl hydrazine in place of hydrazine, the product obtained is a mixture of isomers. These are separated by chromatography to give 5,6-dihydro-l,'5-dimethyl-lH-thiopyranoC3,2-c:5,4-c'ldipy- 0009 razole and 5,6-dihydro-2,6-dimethyl-2H-thiopyrano[3,2-c:- 5,4-c' Idipyrazole.
EXAMPLE 3 A solution of 1.06 g of 3-chloroperoxybenzoic acid in ml of tetrahydrofuran was added dropwise to a solution of 5,6-dihydro-6-methyl-lH-thiopyrano[3,2-c:5,4-c' Idipyrazole in 20 ml of tetrahydrofuran maintained at -15 0
C.
The mixture was stirred at -1.5 0 C for 3 hours and the solid which formed was separated by filtration and dried to give yellow powdery crystals (93% yield). Recrystallization of this solid from ethanol gave 5,6-dihydro-6-methyl-lH-thiopyrano[3f2-c35,4-c']dipyrazole 4-oxide melting at greater than 270 0
C.
S00 EXAMPLE 4, A solution of 7#9 g of 85% 3-chi ,,Ptneroxybenzoic acid in 50 ml of dichloromethane was added dropwise to an icecold solution of 5,6-dihydro-6-methyl-lH-thiopyrano(3,2c:5,4-clJdipyrazole in 100 ml of dichioromethane. The mixture was stirred at room temperature for 24 hou~rs and the solvent was removed under reduced pressure. Trituration of P101259-8 -athe residue with tetrahydrofuran gave an orange-yellow solid (67% yield) melting at about 238 0 C with decomposition. Recrystallization of this solid from methanol gave 5,6-dihydro-6-methyl-lH-thiopyrano(3,2-c:5,4-c'idipyrazole 4,'-dioxide melting at greater than 270 0
C.
C
9029 9
Claims (4)
- 6. A process according to Claim 4 for preparing 5,6- dihydro-6-methyl-lH-thiopyrano(3,2-c:5,4-c' ]dipyrazole which comprises reacting hydrazine with 1,4,5,7-tetrahydro- -iethyl-4-oxothiopyrano[ 3,4-c C, 4 C. 4 4 tt~ d 4 -14- M0 1259 r- i i
- 7. A method for alleviating bronchial spasm in mammals which comprises administering to a mammal in need thereof a bronchodilating amount of a compound of the formula wherein R 1 R 2 R 3 and R 4 are each independently hydrogen or methyl with R 1 and R 3 being positioned on one of the nitrogens in their respective rings with the other nitrogen then being doubly bonded to the adjacent carbon; the dotted lines indicate the presence of two conjugated double bonds with the specific position of the double bonds being determined by the position of the R 1 and R 3 substituents; and n is 0, 1 or 2.
- 8. A compound as claimed in claim 1, substantially as 0t44 hereinbefore described with reference to any one of the Bt Examples.
- 9. A process as claimed in claim 4, substantially as ,8oj hereinbefore described with reference to any one of the Examples. DATED: 18th January, 1988 So PHILLIPS ORMONDE FITZPATRICK "a Attorneys for: MERRELL DOW PHARMACEUTICALS INC. L' a i
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/007,308 US4734431A (en) | 1987-01-27 | 1987-01-27 | Thiopyranodipyrazoles and their use as bronchodilators |
US007308 | 1987-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1072688A AU1072688A (en) | 1988-07-28 |
AU595091B2 true AU595091B2 (en) | 1990-03-22 |
Family
ID=21725411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU10726/88A Ceased AU595091B2 (en) | 1987-01-27 | 1988-01-22 | Thiopyranodipyrazoles |
Country Status (21)
Country | Link |
---|---|
US (1) | US4734431A (en) |
EP (1) | EP0276835B1 (en) |
JP (1) | JP2562642B2 (en) |
KR (1) | KR960010456B1 (en) |
CN (1) | CN1021442C (en) |
AT (1) | ATE86999T1 (en) |
AU (1) | AU595091B2 (en) |
CA (1) | CA1324606C (en) |
DE (1) | DE3879235T2 (en) |
DK (1) | DK35288A (en) |
ES (1) | ES2054711T3 (en) |
FI (1) | FI87217C (en) |
GR (1) | GR3007404T3 (en) |
HU (1) | HU198724B (en) |
IE (1) | IE880194L (en) |
IL (1) | IL85186A (en) |
NO (1) | NO166368C (en) |
NZ (1) | NZ223258A (en) |
PH (1) | PH24997A (en) |
PT (1) | PT86626B (en) |
ZA (1) | ZA88528B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3158619A (en) * | 1962-06-14 | 1964-11-24 | Searle & Co | Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives |
US4042373A (en) * | 1976-06-02 | 1977-08-16 | E. I. Du Pont De Nemours And Company | 2-Aryl-3-chloro-2,4,6,7-tetrahydrothiopyrano[4,3-c]-pyrazoles |
US4077956A (en) * | 1976-08-30 | 1978-03-07 | E. R. Squibb & Sons, Inc. | 5-Substituted derivatives of dipyrazolo[1,5-a:4',3'-e]pyrazine-6-carboxylic acids and esters |
US4355164A (en) * | 1981-05-18 | 1982-10-19 | Usv Pharmaceutical Corporation | Pyridothienopyridazine anti-allergy compounds |
-
1987
- 1987-01-27 US US07/007,308 patent/US4734431A/en not_active Expired - Lifetime
-
1988
- 1988-01-21 NZ NZ223258A patent/NZ223258A/en unknown
- 1988-01-21 CA CA000557075A patent/CA1324606C/en not_active Expired - Fee Related
- 1988-01-21 PH PH36377A patent/PH24997A/en unknown
- 1988-01-22 AU AU10726/88A patent/AU595091B2/en not_active Ceased
- 1988-01-22 FI FI880285A patent/FI87217C/en not_active IP Right Cessation
- 1988-01-25 IL IL85186A patent/IL85186A/en unknown
- 1988-01-26 KR KR1019880000563A patent/KR960010456B1/en not_active IP Right Cessation
- 1988-01-26 DK DK035288A patent/DK35288A/en not_active Application Discontinuation
- 1988-01-26 HU HU88295A patent/HU198724B/en not_active IP Right Cessation
- 1988-01-26 PT PT86626A patent/PT86626B/en not_active IP Right Cessation
- 1988-01-26 ZA ZA88528A patent/ZA88528B/en unknown
- 1988-01-26 NO NO880340A patent/NO166368C/en unknown
- 1988-01-26 CN CN88100342A patent/CN1021442C/en not_active Expired - Fee Related
- 1988-01-26 IE IE880194A patent/IE880194L/en unknown
- 1988-01-27 ES ES88101182T patent/ES2054711T3/en not_active Expired - Lifetime
- 1988-01-27 JP JP63014784A patent/JP2562642B2/en not_active Expired - Fee Related
- 1988-01-27 DE DE8888101182T patent/DE3879235T2/en not_active Expired - Fee Related
- 1988-01-27 AT AT88101182T patent/ATE86999T1/en not_active IP Right Cessation
- 1988-01-27 EP EP88101182A patent/EP0276835B1/en not_active Expired - Lifetime
-
1993
- 1993-03-18 GR GR930400573T patent/GR3007404T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK35288A (en) | 1988-07-28 |
FI880285A (en) | 1988-07-28 |
FI87217B (en) | 1992-08-31 |
NZ223258A (en) | 1989-11-28 |
NO880340L (en) | 1988-07-28 |
PT86626A (en) | 1988-02-01 |
KR880009028A (en) | 1988-09-13 |
CN1021442C (en) | 1993-06-30 |
IL85186A (en) | 1992-02-16 |
NO166368B (en) | 1991-04-02 |
ZA88528B (en) | 1988-09-28 |
JPS63192779A (en) | 1988-08-10 |
HU198724B (en) | 1989-11-28 |
US4734431A (en) | 1988-03-29 |
KR960010456B1 (en) | 1996-08-01 |
IL85186A0 (en) | 1988-07-31 |
DK35288D0 (en) | 1988-01-26 |
DE3879235D1 (en) | 1993-04-22 |
FI87217C (en) | 1992-12-10 |
NO166368C (en) | 1991-07-10 |
GR3007404T3 (en) | 1993-07-30 |
CA1324606C (en) | 1993-11-23 |
NO880340D0 (en) | 1988-01-26 |
CN88100342A (en) | 1988-09-14 |
DE3879235T2 (en) | 1993-06-24 |
IE880194L (en) | 1988-07-27 |
AU1072688A (en) | 1988-07-28 |
ATE86999T1 (en) | 1993-04-15 |
EP0276835A1 (en) | 1988-08-03 |
ES2054711T3 (en) | 1994-08-16 |
FI880285A0 (en) | 1988-01-22 |
EP0276835B1 (en) | 1993-03-17 |
HUT48630A (en) | 1989-06-28 |
JP2562642B2 (en) | 1996-12-11 |
PH24997A (en) | 1990-12-26 |
PT86626B (en) | 1991-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE49077B1 (en) | 5-(4-pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)thiazole,process for its preparation and medical composition | |
JPH0499768A (en) | 4-(4-phenylpyridin-2-yl)piperazine-1-oxide derivative | |
CA1256105A (en) | Substituted 1,8-naphthyridinones, processes for their preparation and pharmaceutical compositions containing them | |
JPH0249787A (en) | Thienotriazolodiazepine compound and pharmaceutical use thereof | |
US4487930A (en) | 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines | |
AU595091B2 (en) | Thiopyranodipyrazoles | |
DK149753B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF MORPHINE DERIVATIVES | |
US4391806A (en) | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators | |
US4391807A (en) | 6-Substituted tetrahydroimidazo[2,1-a]phthalazines and use as bronchodilators | |
EP0276833B1 (en) | Dipyrazoles useful as bronchodilators | |
US4734429A (en) | Cycloalkane[1,2-c:4,3-c']dipyrazoles and their use as bronchodilators | |
US4485106A (en) | Substituted tetrahydrotetrazolo[5,1-a]phthalazines | |
FI88033C (en) | Process for the preparation of pharmacologically valuable cyclobuta, cyclopenta and 7,8,9,10-tetrahydrobenzo / c // 1,8 / naphthyridine-6-derivatives | |
CA1334294C (en) | Substituted imidazol[2,1-b]quinazolin-5(3h)-ones and related tricyclic compounds | |
JPH02286679A (en) | Imidazopyridine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |